Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MARK3 | P27448 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491110 | 0.87 | KDR (0.41) | AURKAAURKBCCKBRTP53MAPT | |
| SCHEMBL2516486 | 0.84 | NPC1 (0.45) | AURKAAURKBTP53LMNAMEN1 | |
| SCHEMBL13341410 | 0.83 | AURKA (0.43) | AURKAAURKBMAPTLMNASCN9A | |
| SCHEMBL13368132 | 0.80 | AURKA (0.53) | AURKAAURKBTP53MAPTLMNA | |
| SCHEMBL13341574 | 0.80 | NPC1 (0.48) | AURKAAURKBTP53LMNAMEN1 | |
| SCHEMBL13341602 | 0.80 | AURKA (0.42) | AURKAAURKBCNR2TP53LMNA | |
| SCHEMBL13341571 | 0.80 | ALDH1A1 (0.44) | AURKAAURKBMEN1KMT2APOLB | |
| SCHEMBL13341569 | 0.80 | AURKA (0.40) | AURKAAURKBLMNARAF1BRAF | |
| SCHEMBL2485551 | 0.79 | XBP1 (0.41) | AURKAAURKBMAPTMEN1KMT2A | |
| SCHEMBL2486891 | 0.79 | RAB9A (0.47) | AURKAAURKBTP53LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756112-B1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1598353-A1 | Pyrrolobenzimidazolones and their use as antiproliferative agents | Boehringer Ingelheim International GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | MKI67, CCNI, CCNA1 | AURKA 268/4885AURKB 215/4885DGAT1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.